Nathalie Accart
Research Subjects
Research Interests
Nathalie Accart has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Cristina Niculescu
Transgene S.A., Boulevard Gonthier d’Andernach, Parc d’Innovation, 67405 Cedex Illkirch Graffenstaden, France
1 shared publication - Jean-Marc Limacher
Hôpital Pasteur, Service d’Onco-hématologie, Colmar, France
1 shared publication - Jean-Yves Bonnefoy
ElsaLysbiotech, 650 Boulevard Gonthier d'Andernach, Parc d'Innovation, F-67400 Illkirch Graffenstaden, France
1 shared publication - Marie-Pierre Chenard
Département de pathologie, CHU de Hautepierre, 1, avenue Molière, 67098 Strasbourg, France
1 shared publication - Mirjana Urosevic-Maiwald
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
1 shared publication - Nadine Kehrer
Transgene S.A., Boulevard Gonthier d’Andernach, Parc d’Innovation, 67405 Cedex Illkirch Graffenstaden, France
1 shared publication
Latest Publications
- Open Access
- 25 September 2013
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 11 (1) , 226
Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042
Background: Primary cutaneous lymphomas (CLs), characterized by an accumulation of clonal T or B lymphocytes preferentially localized in the skin, have been successfully treated with interferons (IFNs) which counterbalance the Th2-immunosuppressive state associated with this pathology. In a phase I/II clinical trial, we correlated the local immune infiltrate and the anti-tumor effects of repeated intralesional administrations of an adenovirus vector expressing human interferon-gamma (IFN-g) termed TG1042, in patients with advanced primary cutaneous T-cell lymphomas (CTCL) or multilesional cutaneous B-cell lymphomas (CBCL). Methods: For each patient, variation in time of specific lymphocyte populations, defined by immunohistochemical stainings, was assessed in biopsies of injected lesions. For each patient, the change in local immune response was associated with the patient’s objective response at the end of the study. Results: Immunohistochemical analyses of biopsies indicate that infiltration of CD8+ T lymphocytes and of TIA-1+ cytotoxic T-cells in lesions injected with TG1042 correlates with clinical benefit. Conclusions: These data suggest for the first time that a CD8+ cytotoxic infiltrate, induced by local expression of IFN-g correlates with a clinical response. Trial registration: The phase I step (TG1042.01) does not have a registration number. The phase II step (TG1042.06) registration number was NCT00394693.
- 25 September 2013
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 11 (1) , 226
Open AccessLymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042
Background: Primary cutaneous lymphomas (CLs), characterized by an accumulation of clonal T or B lymphocytes preferentially localized in the skin, have been successfully treated with interferons (IFNs) which counterbalance the Th2-immunosuppressive state associated with this pathology. In a phase I/II clinical trial, we correlated the local immune infiltrate and the anti-tumor effects of repeated intralesional administrations of an adenovirus vector expressing human interferon-gamma (IFN-g) termed TG1042, in patients with advanced primary cutaneous T-cell lymphomas (CTCL) or multilesional cutaneous B-cell lymphomas (CBCL). Methods: For each patient, variation in time of specific lymphocyte populations, defined by immunohistochemical stainings, was assessed in biopsies of injected lesions. For each patient, the change in local immune response was associated with the patient’s objective response at the end of the study. Results: Immunohistochemical analyses of biopsies indicate that infiltration of CD8+ T lymphocytes and of TIA-1+ cytotoxic T-cells in lesions injected with TG1042 correlates with clinical benefit. Conclusions: These data suggest for the first time that a CD8+ cytotoxic infiltrate, induced by local expression of IFN-g correlates with a clinical response. Trial registration: The phase I step (TG1042.01) does not have a registration number. The phase II step (TG1042.06) registration number was NCT00394693.